NATERA, INC. (NTRA) Operating Margin
- Operating margin · 12 months: Value -10.70%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -10.70% | Operating income / revenue. Period ending 2026-06-30. $-289.67M ÷ $2.71B × 100 ≈ -10.70% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -289.67M USD | Operating Income (Loss) |
| Revenue | 2.71B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 787.38M USD | Research and Development Expense |
| Selling, general and administration | 1.25B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-289.67M | $2.71B | (m) | $787.38M | $1.25B | -10.70% |
| 2026-03-31 | $-324.25M | $2.50B | (m) | $705.73M | $1.24B | -12.97% |
| 2025-12-31 | $-309.91M | $2.31B | (m) | $624.11M | $1.18B | -13.44% |
| 2025-09-30 | $-351.87M | $2.12B | (m) | $578.38M | $1.12B | -16.62% |
| 2025-06-30 | $-293.63M | $1.96B | (m) | $501.90M | $1.03B | -14.95% |
| 2025-03-31 | $-227.16M | $1.83B | (m) | $444.58M | $913.90M | -12.41% |
| 2024-12-31 | $-222.29M | $1.70B | (m) | $404.14M | $841.31M | -13.10% |
| 2024-09-30 | $-242.09M | $1.53B | (m) | $357.64M | $767.83M | -15.80% |
| 2024-06-30 | $-313.73M | $1.36B | (m) | $337.94M | $708.41M | -23.06% |
| 2024-03-31 | $-382.26M | $1.21B | (m) | $327.01M | $662.96M | -31.63% |
| 2023-12-31 | $-446.25M | $1.08B | (m) | $320.68M | $618.31M | -41.22% |
| 2023-09-30 | $-503.48M | $988.72M | (m) | $325.63M | $600.70M | -50.92% |
| 2023-06-30 | $-511.55M | $931.05M | (m) | $313.90M | $593.62M | -54.94% |
| 2023-03-31 | $-542.21M | $867.85M | (m) | $318.31M | $590.58M | -62.48% |
| 2022-12-31 | $-541.04M | $820.22M | (m) | $316.42M | $588.59M | -65.96% |
| 2022-09-30 | $-538.93M | $776.00M | (m) | $300.31M | $591.53M | -69.45% |
| 2022-06-30 | $-570.08M | $723.48M | (m) | $333.26M | $572.35M | -78.80% |
| 2022-03-31 | $-542.29M | $667.30M | (m) | $304.43M | $550.34M | -81.27% |
| 2021-12-31 | $-468.17M | $625.49M | (m) | $264.21M | $511.03M | -74.85% |
| 2021-09-30 | $-402.48M | $564.84M | (m) | $224.78M | $458.35M | -71.26% |
| 2021-06-30 | $-308.06M | $504.86M | (m) | $152.75M | $405.55M | -61.02% |
| 2021-03-31 | $-244.42M | $449.31M | (m) | $122.00M | $346.28M | -54.40% |
| 2020-12-31 | $-216.28M | $391.00M | (m) | $100.03M | $303.63M | -55.31% |
| 2020-09-30 | $-177.12M | $361.87M | (m) | $82.65M | $268.13M | -48.95% |
| 2020-06-30 | $-142.44M | $341.63M | (m) | $69.03M | $249.17M | -41.69% |
| 2020-03-31 | $-119.41M | $329.52M | (m) | $58.15M | $228.03M | -36.24% |
| 2019-12-31 | $-116.29M | $302.33M | (m) | $51.36M | $206.18M | -38.46% |
| 2019-09-30 | $-111.20M | $286.05M | $163.47M | $49.13M | $188.72M | -38.87% |
| 2019-06-30 | $-117.28M | $273.42M | $162.81M | $48.72M | $170.38M | -42.89% |
| 2019-03-31 | $-115.86M | $262.14M | $160.63M | $48.45M | $160.78M | -44.20% |
| 2018-12-31 | $-114.63M | $257.65M | $158.08M | $51.35M | $154.87M | -44.49% |
| 2018-09-30 | $-130.22M | $244.05M | (m) | $51.60M | $162.68M | -53.36% |
| 2018-06-30 | $-128.84M | $234.68M | (m) | $51.82M | $158.78M | -54.90% |
| 2018-03-31 | $-129.99M | (m) | (m) | $51.75M | $155.65M | (m) |
| 2017-12-31 | $-134.03M | $210.94M | (m) | $50.06M | $155.31M | -63.54% |
| 2017-09-30 | $-126.82M | $206.47M | (m) | $48.50M | $143.92M | -61.42% |
| 2017-06-30 | $-128.44M | $203.71M | (m) | $47.24M | $144.38M | -63.05% |
| 2017-03-31 | $-123.91M | $202.07M | (m) | $45.75M | $143.30M | -61.32% |
| 2016-12-31 | $-96.49M | $217.07M | (m) | $41.86M | $136.13M | -44.45% |
| 2016-09-30 | $-76.12M | $220.69M | (m) | $38.41M | $129.01M | -34.49% |
| 2016-06-30 | $-70.21M | $211.72M | (m) | $34.40M | $121.95M | -33.16% |
| 2016-03-31 | $-63.17M | $204.82M | (m) | $30.84M | $116.81M | -30.84% |
| 2015-12-31 | $-59.84M | $190.35M | (m) | $27.71M | $109.64M | -31.43% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $179.43M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $665.00K | $159.29M | (m) | $17.29M | $62.94M | 0.42% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-25.27M | $55.17M | (m) | $11.55M | $31.61M | -45.80% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |